Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.80 Analyst target: $8.09 Upside: 911.25%
Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.
See the full interactive analysis & chart →Informational only — not investment advice.